Aptus Capital Advisors LLC Takes Position in Xilio Therapeutics, Inc. (NASDAQ:XLO)

Aptus Capital Advisors LLC bought a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 41,000 shares of the company’s stock, valued at approximately $39,000.

Several other large investors have also recently bought and sold shares of the business. Gilead Sciences Inc. purchased a new stake in shares of Xilio Therapeutics during the fourth quarter worth $8,696,000. Takeda Pharmaceutical Co. Ltd. acquired a new position in Xilio Therapeutics in the 4th quarter worth about $1,416,000. Geode Capital Management LLC raised its stake in shares of Xilio Therapeutics by 6.0% during the 4th quarter. Geode Capital Management LLC now owns 358,422 shares of the company’s stock worth $342,000 after purchasing an additional 20,230 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Xilio Therapeutics by 11.4% during the 4th quarter. Renaissance Technologies LLC now owns 296,617 shares of the company’s stock valued at $283,000 after buying an additional 30,317 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Xilio Therapeutics in the 4th quarter valued at approximately $48,000. 54.29% of the stock is owned by institutional investors and hedge funds.

Xilio Therapeutics Stock Performance

Shares of XLO opened at $0.71 on Friday. The firm has a market cap of $36.76 million, a PE ratio of -0.41 and a beta of -0.27. The firm’s 50 day moving average price is $0.76 and its 200 day moving average price is $0.92. Xilio Therapeutics, Inc. has a twelve month low of $0.62 and a twelve month high of $1.70.

Xilio Therapeutics (NASDAQ:XLO) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.28). The firm had revenue of $2.93 million for the quarter, compared to analyst estimates of $42.00 million. On average, sell-side analysts anticipate that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current fiscal year.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.